FDA Accepts Supplemental NDA for IBTROZI® (taletrectinib) with Updated DoR in Advanced ROS1+ve NSCLC May 12, 2026
FDA Commissioner’s National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma May 12, 2026
Fast Track Designation for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma May 12, 2026
US FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci) for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) May 12, 2026
FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer May 6, 2026
Ph 2/3 Clinical Trial Application submitted to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer May 6, 2026
US FDA Accepts NDA for Zipalertinib for the Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations May 6, 2026
US FDA RMAT Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies May 6, 2026
FDA ODAC didn’t reach a majority vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR+ve HER2neg breast cancer May 6, 2026
NDA Submission initiated from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence RTOR Program May 6, 2026
Taletrectinib (IBTROZI®) Added as Recommended Option to NCCN Guidelines for CNS Cancers April 28, 2026
FDA Accepts for Priority Review Supplemental BLA for Ziihera® (zanidatamab-hrii) Combo in 1L HER2+ Locally Advanced or Metastatic GEA April 28, 2026
Type C meeting with FDA provides alignment on design of a pivotal clinical study to support approval of pelareorep in patients with unresectable metastatic SCAC April 28, 2026